Uhthoff's phenomena in MS - Clinical features and pathophysiology

Nature Reviews Neurology

Volumn 9, Issue 9, 2013, Pages 535-540

  Frohman, Teresa C ^a   Davis, Scott L ^b   Beh, Shin ^a   Greenberg, Benjamin M ^a   Remington, Gina ^a   Frohman, Elliot M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b SOUTHERN METHODIST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; CORTICOSTEROID; ION CHANNEL; POTASSIUM CHANNEL; SODIUM CHANNEL;

ACTION POTENTIAL; CLINICAL FEATURE; COOLING; DEMYELINATION; DISEASE EXACERBATION; EVOKED RESPONSE; EYE MOVEMENT; HEATING; HUMAN; MEDIAL LONGITUDINAL BUNDLE; MULTIPLE SCLEROSIS; NERVE CONDUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOPLEGIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYMPTOM; THERMOREGULATION; UHTHOFF PHENOMENA; VISUAL DISORDER;

HISTORY, 19TH CENTURY; HUMANS; MULTIPLE SCLEROSIS;

EID: 84883743102     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2013.98     Document Type: Review

References (26)

1. Smith, K. J. & McDonald, W. I. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354, 1649-1673 (1999). (Pubitemid 29534432)
2. Uhthoff, W. Untersuchungen über die bei der multiplen Herdsklerose vorkommenden Augenstörungen [German]. Arch. Psychiatr. Nervenkr. 21, 303-420 (1890).
3. Rushton, W. A. Initiation of the propagated disturbance. Proc. R. Soc. Lond. B Biol. Sci. 124, 210-243 (1937).
4. Davis, S. et al. Modeling Uhthoff's phenomenon in MS patients with internuclear ophthalmoparesis. Neurology 70, 1098-1106 (2008). (Pubitemid 351464766)
5. Frohman, T. C., Davis, S. L. & Frohman, E. M. Modeling the mechanisms of Uhthoff's phenomenon in MS patients with internuclear ophthalmoparesis. Ann. NY Acad. Sci. 1233, 313-319 (2011).
6. Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69, 292-302 (2011).
7. Fromont, A. et al. Long-lasting and isolated Uhthoff's phenomenon after effort preceding multiple sclerosis [French]. Rev. Neurol. (Paris) 166, 61-65 (2009).
8. Smith, K. J. Conduction properties of central demyelinated and remyelinated axons, and their relation to symptom production in demyelinating disorders. Eye (Lond.) 8, 224-237 (1994). (Pubitemid 24189832)
9. McDonald, W. I. & Sears, T. A. Effect of demyelination on conduction in the central nervous system. Nature 221, 182-183(1969).
10. Frohman, E. M. et al. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Committee of the American Academy of Neurology. Neurology 61, 602-611 (2003). (Pubitemid 37082595)
11. Frohman, E. M., Racke, M. K. & Raine, C. S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 354, 942-955 (2006).
12. Mills, D. et al. Break in binocular fusion during head turning in MS patients with INO. Neurology 71, 458-460 (2008).
13. Wingerchuk, D. & Rodriguez, M. Premenstrual multiple sclerosis pseudoexacerbations: role of body temperature and prevention with aspirin. Arch. Neurol. 63, 1005-1008 (2006). (Pubitemid 44036304)
14. Selhorst, J. B. & Saul, R. F. Uhthoff and his symptom. J. Neuroophthalmol. 15, 63-69 (1995).
15. Zee, D. S. Internuclear ophthalmoplegia: pathophysiology and diagnosis. Baillieres Clin. Neurol. 1, 455-470 (1992).
16. Frohman, T. C. et al. Pearls & Oy-sters: the medial longitudinal fasciculus (MLF) in ocular motor physiology. Neurology 70, e57-e67 (2008). (Pubitemid 351589514)
17. Ventre, J., Vighetto, A., Bailly, G. & Prablanc, C. Saccade metrics in multiple sclerosis: versional velocity dysconjugacy as the best clue? J. Neurol. Sci. 102, 144-149 (1991).
18. Frohman, E. M. et al. Quantitative oculographic characterisation of internuclear ophthalmoparesis in multiple sclerosis: the versional dysconjugacy index Z score. J. Neurol. Neurosurg. Psychiatry 73, 51-55 (2002). (Pubitemid 34713012)
19. Frohman, E. M. et al. MRI characteristics of the MLF in MS patients with chronic internuclear ophthalmoparesis. Neurology 57, 762-768 (2001). (Pubitemid 32845491)
20. Frohman, T. C. et al. Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculography. Neurology 61, 848-850 (2003). (Pubitemid 37174490)
21. Frohman, E. M., O'Suilleabhain, P., Dewey, R. B. Jr, Frohman, T. C. & Kramer, P. D. A new measure of dysconjugacy in INO: the first-pass amplitude. J. Neurol. Sci. 210, 65-71 (2003). (Pubitemid 36539407)
22. Frohman, E. M. et al. Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics 4, 618-626 (2007). (Pubitemid 47499290)
23. Boster, A. et al. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol. 7, 173-183 (2008).
24. Malhotra, A. S. & Goren, H. The hot bath test in the diagnosis of multiple sclerosis. JAMA 246, 1113-1114 (1981). (Pubitemid 11051856)
25. Polman, C. H., Bertelsmann, F. W., van Loenen, A. C. & Koetsier, J. C. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch. Neurol. 51, 292-296 (1994). (Pubitemid 24088417)
26. Goodman, A. D. et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373,732-738 (2009).